The following report outlines a case of newly diagnosed adult-onset Still’s disease (AOSD) complicated by macrophage activation syndrome (MAS) in a previously healthy and active 32-year-old man who had emigrated from Africa to the U.S. Case A man with no prior medical history presented with acute-onset polyarthritis, fevers and fatigue that began one month previously….
The second annual Global Rheumatology Summit focused on climate change, conflict and migration, as well as other global issues in rheumatology.
In 1949, the first description of patients with rheumatoid arthritis (RA) given cortisone sent shockwaves through the medical community, quickly capturing the public imagination as well. The paradigm-shifting report paved the way for the use of cortisone and related drugs in RA and many other medical conditions.1 The following is a discussion of some of…
PHILADELPHIA—The term pseudogout has been a source of confusion among rheumatologists, especially as our understanding of calcium pyrophosphate crystal deposition (CPPD) disease has become more nuanced. This condition has many complex and interesting facets that warrant closer investigation. An ACR Convergence 2022 session sought to update the audience on the progress to date in developing…
PHILADELPHIA—William “Bill” R. Palmer, MD, MACR, was the first board-certified rheumatologist in Omaha, Neb., where he spent his entire 43-year clinical career and established himself as a great clinician, mentor and educator. Although Dr. Palmer passed away from metastatic thyroid cancer in August 2021, his memory lives on through his physician colleagues and at ACR…
This ACR Convergence 2022 session focused on ways to improve health equity in Indigenous populations.
PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…
The Plenary III Session reviewed the results of the SAPHYR trial of sarilumab in PMR patients, as well as the WE-CAN study on the impact of a community-level diet & exercise program on knee pain in patients with knee osteoarthritis.
In this comparative effectiveness clinical trial, Yan et al. set out to compare nontitrated, low-dose benzbromarone (not approved in the U.S.), a renal urate transporter 1 inhibitor, with low-dose febuxostat as the first-line therapy in gout patients with renal uric acid underexcretion.
PHILADELPHIA—“At age 12, I was diagnosed with psoriasis (PsO), followed by a diagnosis of psoriatic arthritis (PsA) at age 30,” said Ashley Krivohlavek of Oklahoma City in a poster presentation at ACR Convergence 2022. “I’m now 38.” Ms. Krivohlavek’s Story In 2020, I had been on an infused biologic for 18 months, but my…